Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial

Daneshi-Maskooni, Milad; Keshavarz, Seyed Ali; Qorbani, Mostafa; Mansouri, Siavash; Alavian, Seyed Moayed; Badri-Fariman, Mahtab; Jazayeri-Tehrani, Seyed Ali; Sotoudeh, Gity

doi:10.1186/s12986-018-0297-4

Cited by 45 publications

(38 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Spices and their bioactive compounds are also beneficial to FLD patients. Several double-blind randomized placebo-controlled clinical trials showed that the intake of 500 mg of green cardamom 3 times per day for 3 months could decrease the degree of fatty liver in NAFLD patients, accompanied by decreasing the levels of ALT, CRP, TNF- α , and IL-6, as well as increasing the serum level of SIRT1 [ 159 ]. Besides, the intake of 70 mg per day of curcumin for 8 weeks significantly reduced fatty liver in NAFLD patients, accompanied by improving the serum levels of liver enzymes, lipid profiles, glucose, and glycated hemoglobin [ 160 ].…”

Section: Clinical Trials Of Plant-based Foods and Their Bioactive mentioning

confidence: 99%

Plant‐Based Foods and Their Bioactive Compounds on Fatty Liver Disease: Effects, Mechanisms, and Clinical Application

Gan

Shang

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Fatty liver disease (FLD), including nonalcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD), is a serious chronic metabolic disease that affects a wide range of people. Lipid accumulation accompanied by oxidative stress and inflammation in the liver is the most important pathogenesis of FLD. The plant-based, high-fiber, and low-fat diet has been recommended to manage FLD for a long time. This review discusses the current state of the art into the effects, mechanisms, and clinical application of plant-based foods in NAFLD and AFLD, with highlighting related molecular mechanisms. Epidemiological evidence revealed that the consumption of several plant-based foods was beneficial to alleviating FLD. Further experimental studies found out that fruits, spices, teas, coffee, and other plants, as well as their bioactive compounds, such as resveratrol, anthocyanin, curcumin, and tea polyphenols, could alleviate FLD by ameliorating hepatic steatosis, oxidative stress, inflammation, gut dysbiosis, and apoptosis, as well as regulating autophagy and ethanol metabolism. More importantly, clinical trials confirmed the beneficial effects of plant-based foods on patients with fatty liver. However, several issues need to be further studied especially the safety and effective doses of plant-based foods and their bioactive compounds. Overall, certain plant-based foods are promising natural sources of bioactive compounds to prevent and alleviate fatty liver disease.

show abstract

Section: Clinical Trials Of Plant-based Foods and Their Bioactive mentioning

confidence: 99%

Plant‐Based Foods and Their Bioactive Compounds on Fatty Liver Disease: Effects, Mechanisms, and Clinical Application

Gan

Shang

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…TNF-α is a pro-inflammatory biomarkers which is abundantly produced in adipose tissue macrophages. (Figure 4) High level of TNF-α increase dyslipidemia, insulin resistance, and secretion of IL-6 [24,25]. High levels of this cytokine cause proliferation of theca intra cells, which leads to hyperplasia and an increase number of the follicles.…”

Section: Discussionmentioning

confidence: 99%

“…The IL-6r gene maps to human chromosome 1q21 in which is responsible of IL-6 production [26]. IL-6 is an endocrine inflammatory cytokine that produced in many body cells for example adipose tissue in acute and chronic inflammation [24]. High excess IL-6 level was associated with obesity, insulin resistance, hyperandrogenism, and ovarian dysfunction [25,1,5].…”

Section: Discussionmentioning

confidence: 99%

Green Cardamom Plus Low Calorie Diet Can Decrease Inflammatory Genes Expression Among Obese Women With Poly Cystic Ovarian Syndrome, A Double Blind Randomized Clinical Trial

Cheshmeh

Ghayyem

Khamooshi

et al. 2021

Preprint

View full text Add to dashboard Cite

PurposePolycystic ovary syndrome (PCOS) is a common cause of endocrine disorder and infertility among womenin which is related with low grade inflammation. Therefore, this current randomized, double-blind, placebo-controlledclinical trial assessed the effects of green cardamom supplementation on inflammatory markers and gene expressionamong obese women with PCOS.MethodsWe included 194 obese PCOS women that gave all of them low calorie diet. These subjects were randomlydivided in two studied groups including intervention with 3 g/day green cardamom (n=99) and placebo groups (n=95).Anthropometric indices, androgen hormones, and inflammatory factors (tumor necrosis factor-a (TNF-α), Interleukin6 (IL-6), and C- reactive protein (CRP)) were assessed before and after four months intervention. Their TNF-α, IL-6,and CRP genes expression level were measured using reverse transcription-polymerase chain reaction (RT-PCR)method.ResultsAnthropometric indices were improved in both two studied groups (P<0.001). Among androgen hormonesluteinizing hormone, androstenedione, and dehydroepiandrosterone were significantly decreased (P<0.001), as wellas, follicle-stimulating hormone was significantly increased (P<0.001) in the green cardamom group. Our findingsshowed that TNF-α, IL-6, and CRP serum were significantly decreased after the intervention with green cardamomplus low calorie diet (P<0.001). In addition, the expression level of TNF-α and CRP genes were significantly decreasedin intervention groups (P<0.001).ConclusionsThis present study support the beneficial anti-inflammatory effect of green cardamom on theinflammatory status in the PCOS women.Level of evidenceLevel I, randomized clinical trialTrial registrationThis trial was registered with the Iranian Clinical Trials Registry (registration number:IRCT20200608047697N1). 1 August, 2020; https://www.irct.ir/trial/48748

show abstract

“…Furthermore, the decrease in LDL-c was significant in the unadjusted model and showed a trend in the adjusted model. Based on our previous findings in the other part of this trial [ 59 ], compared with placebo, GC significantly diminished serum alanine transaminase (ALT) by 127% and heightened Sirtuin 1 (Sirt1) by 40% ( P < 0.05). In addition, the fall in BMI showed a trend among GC group in comparison with the placebo group.…”

Section: Discussionmentioning

confidence: 99%

Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial

Daneshi-Maskooni

Keshavarz

Qorbani

et al. 2019

BMC Complement Altern Med

Self Cite

View full text Add to dashboard Cite

BackgroundDespite the reported health effects of cardamom on dyslipidemia, hepatomegaly, and fasting hyperglycemia, no human research has studied its potency in non-alcoholic fatty liver disease (NAFLD) as the hepatic part of metabolic syndrome. Our aim was determining the effects of green cardamom (GC) on serum glucose indices, lipids, and irisin level among overweight or obese NAFLD patients.MethodsThe place of participant recruitment was the polyclinic of the National Iranian Oil Company (NIOC) central hospital in Tehran. Based on the ultrasonography and eligibility criteria, 87 participants were randomly divided into two groups as cardamom (n = 43) or placebo (n = 44). The supplementation was two 500 mg capsules 3 times/day with meals for 3 months. Serum irisin, fasting blood sugar (FBS), insulin (FBI), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c) were measured. Quantitative insulin sensitivity check index (QUICKI) and homeostasis model assessment-insulin resistance (HOMA-IR) were also calculated.ResultsIn comparison with placebo, GC significantly increased irisin, HDL-c, and QUICKI and decreased FBI, TG, LDL-c, HOMA-IR, and the grade of fatty liver (P < 0.05). After adjustment for confounders, the changes were similar (P < 0.05) with an exception for LDL-c which had a trend (P = 0.07). The differences in FBS, TC, and body mass index (BMI) were not significant (P > 0.05).ConclusionGC supplement improved the grade of fatty liver, serum glucose indices, lipids, and irisin level among overweight or obese NAFLD patients. The changes in these biomarkers may yield beneficial effects on NAFLD. Further trials on the efficacy of GC for clinical practice are suggested.Trial registrationIranian Registry of Clinical Trials, IRCT2015121317254N4. Registered 27/12/2015,Electronic supplementary materialThe online version of this article (10.1186/s12906-019-2465-0) contains supplementary material, which is available to authorized users.

show abstract

Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial

Cited by 45 publications

References 72 publications

Plant‐Based Foods and Their Bioactive Compounds on Fatty Liver Disease: Effects, Mechanisms, and Clinical Application

Plant‐Based Foods and Their Bioactive Compounds on Fatty Liver Disease: Effects, Mechanisms, and Clinical Application

Green Cardamom Plus Low Calorie Diet Can Decrease Inflammatory Genes Expression Among Obese Women With Poly Cystic Ovarian Syndrome, A Double Blind Randomized Clinical Trial

Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial

Contact Info

Product

Resources

About